glp-1 obesity drug news today sep 30 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio glp-1 obesity drug news today

Jardiance (empagliflozin) 38% CV death reduction vs Mounjaro (tirzepatide) 21% weight loss (EMPA-REG vs SURPASS)

Probiotic supplements work best as part of a comprehensive health strategy that includes balanced nutrition, regular physical activity, quality sleep, and appropriate medical care

In this study we investigated the target occupancy of the dual agonist SAR425899 at the GLP1R in pancreas and GCGR in liver by Positron Emission Tomography/Computed Tomography (PET/CT)

Learn how GLP-1 medications may affect vision, from blurry sight to rare risks, plus potential eye health benefits and when to see an eye doctor.

semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m2 (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m2 (3.3, 6.2)

Data on bone health in the context of calorie restriction and bariatric surgery were also summarized